Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Remodelin (hydrobromide)

Remodelin hydrobromide is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin hydrobromide inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin hydrobromide inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin hydrobromide enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model[1][2][3][4].

Product Specifications

CAS Number

[1622921-15-6]

UNSPSC

12352005

Hazard Statement

H302, H312, H315, H319, H332, H335

Target

Histone Acetyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Remodelin-hydrobromide.html

Concentration

10mM

Purity

99.52

Solubility

DMSO : ≥ 44 mg/mL|H2O : < 0.1 mg/mL

Smiles

N#CC1=CC=C(C2=CSC(N/N=C3CCCC/3)=N2)C=C1.[H]Br

Molecular Formula

C15H15BrN4S

Molecular Weight

363.28

Precautions

H302, H312, H315, H319, H332, H335

References & Citations

[1]Larrieu D, et al. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science. 2014 May 2;344 (6183) :527-32. |[2]Ma N, et.al. Inhibition of N-Acetyltransferase 10 Suppresses the Progression of Prostate Cancer through Regulation of DNA Replication. Int J Mol Sci. 2022 Jun 12;23 (12) :6573. |[3]Balmus G, et.al. Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome. Nat Commun. 2018 Apr 27;9 (1) :1700. |[4]Zhang X, et.al. N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition. Oxid Med Cell Longev. 2019 Jul 1;2019:7561879.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Acta Pharmacol Sin. 2023 Oct;44 (10) :2125-2138.|bioRxiv. 2025 Sep 1:2025.09.01.673489.|Epigenetics. 2024 Dec;19 (1) :2417158.|Heliyon. 2023 Jun 8;9 (6) :e17103.|iScience. 2025 Jun 9;28 (7) :112860.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Oncogene. 2021 Apr;40 (15) :2711-2724.|SSRN. 2025 Jul 28.|Adv Sci (Weinh) . 2025 Dec;12 (46) :e04245.|bioRxiv. 2023 Feb 11.|Cell Death Dis. 2023 Nov 1;14 (11) :712.|Cell Rep. 2023 Jul 17;42 (7) :112810.|J Agric Food Chem. 2022 Jan 12;70 (1) :403-414.|J Hazard Mater. 2025 Oct 19:499:140193.|J Virol. 2024 Jan 23;98 (1) :e0135023.|Life Sci. 2023 Oct 1:330:121948.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

SUFU AAV Vector (Human) (CMV)
45829101 1 µg

SUFU AAV Vector (Human) (CMV)

Ask
View Details
Mmu-miR-467c-5p miRNA Agomir
CMN0522-01 5 nmol

Mmu-miR-467c-5p miRNA Agomir

Ask
View Details
Mmu-miR-467c-5p miRNA Agomir
CMN0522-02 10 nmol

Mmu-miR-467c-5p miRNA Agomir

Ask
View Details
Mmu-miR-467c-5p miRNA Agomir
CMN0522-03 20 nmol

Mmu-miR-467c-5p miRNA Agomir

Ask
View Details
Recombinant Thermoanaerobacter tengcongensis Probable transaldolase (tal)
MBS1366816-01 0.05 mg (E-Coli)

Recombinant Thermoanaerobacter tengcongensis Probable transaldolase (tal)

Ask
View Details
Recombinant Thermoanaerobacter tengcongensis Probable transaldolase (tal)
MBS1366816-02 0.05 mg (Yeast)

Recombinant Thermoanaerobacter tengcongensis Probable transaldolase (tal)

Ask
View Details